Can GLP-1 medications cause hair loss?
GLP-1 medications such as semaglutide and tirzepatide have become widely used for weight loss and metabolic health. These include well-known brand names such as Ozempic, Wegovy, Mounjaro and Zepbound.
A new 2026 systematic review published in Science Progress has added to growing evidence that some people using GLP-1 medications may experience increased hair shedding. The review found that semaglutide and tirzepatide showed the highest reported rates of hair loss signals among GLP-1 therapies, with telogen effluvium and androgenetic alopecia being the most commonly reported hair-loss patterns.
https://journals.sagepub.com/doi/10.1177/00368504261444578
Importantly, this does not necessarily mean the medication directly damages the hair follicle. In many cases, the shedding appears to be linked to rapid weight loss, reduced calorie intake, nutritional changes, or physical stress on the body.
Why can rapid weight loss trigger hair shedding?
The most likely explanation is a condition called telogen effluvium.
Telogen effluvium happens when the body goes through a significant stressor, such as:
- rapid weight loss
- major dietary restriction
- illness or surgery
- hormonal changes
- low protein intake
- iron, vitamin D, zinc or B12 deficiency
When this happens, more hairs than usual can shift from the active growing phase into the resting phase. Several weeks or months later, the person may notice increased shedding, especially when washing, brushing or styling the hair.
The American Academy of Dermatology notes that hair thinning reported with GLP-1 drugs is believed by dermatologists to be related mainly to the sudden weight loss some people experience while taking these medications.
https://www.aad.org/public/everyday-care/skin-care-secrets/prevent-skin-problems/glp1-drugs-and-side-effects
Which GLP-1 drugs are most linked with hair loss?
The 2026 review reported that semaglutide and tirzepatide had the most frequent hair-loss signals in the available evidence. Tirzepatide was especially associated with telogen effluvium, possibly because it can produce greater weight loss in some patients.
https://journals.sagepub.com/doi/10.1177/00368504261444578
These medicines are marketed under different names depending on the indication and country, including:
- Semaglutide: Ozempic, Wegovy
- Tirzepatide: Mounjaro, Zepbound
However, the research is still developing. Current evidence suggests the hair loss is usually temporary and manageable, especially when weight loss stabilises and nutritional intake is corrected.
Is it the drug itself or the weight loss?
This is the key question.
At present, many experts believe the hair shedding is more likely to be an indirect effect of rapid weight loss rather than a direct toxic effect of GLP-1 medication on the hair follicle. Drugs.com’s medical review similarly states that there is no clear evidence that Ozempic, Wegovy, Mounjaro or Zepbound directly cause hair loss; instead, shedding is more likely related to rapid weight loss and telogen effluvium.
https://www.drugs.com/medical-answers/ozempic-wegovy-mounjaro-cause-hair-loss-3575019/
That said, newer studies are now looking more closely at whether certain GLP-1 drugs may carry a higher risk than others. A 2026 Journal of the American Academy of Dermatology cohort study specifically examined new-onset hair loss with semaglutide and tirzepatide, showing that this is now an active area of dermatology research.
https://pubmed.ncbi.nlm.nih.gov/41707704/
Is GLP-1-related hair loss permanent?
In many cases, no.
When the cause is telogen effluvium, the shedding is usually temporary. Once the trigger is corrected — for example, rapid weight loss slows down, calorie intake improves, or deficiencies are treated — the hair cycle often begins to normalise.
Cleveland Clinic notes that telogen effluvium related to rapid weight loss or nutritional issues often improves within 3 to 6 months, although full visual recovery can take longer because hair grows slowly.
https://health.clevelandclinic.org/does-ozempic-cause-hair-loss
However, GLP-1-related shedding can sometimes reveal or worsen an underlying hair condition, such as androgenetic alopecia. In those cases, the person may need a proper hair and scalp assessment rather than assuming the shedding will resolve on its own.
How to reduce the risk of hair loss while using GLP-1 medication
Patients should not stop prescribed medication without speaking to their doctor. Instead, the focus should be on reducing avoidable triggers for shedding.
Helpful steps may include:
- Avoid crash dieting
Very low-calorie intake can increase the risk of telogen effluvium. - Prioritise protein intake
Hair is made from keratin, a protein. Inadequate protein can contribute to shedding. - Check key nutrients
Iron/ferritin, vitamin D, B12, zinc and thyroid markers may be relevant in people with unexplained hair loss. - Aim for steady weight loss
Slower, medically supervised weight reduction may be less stressful for the hair cycle. - Seek early advice if shedding continues
If shedding lasts more than a few months, or if thinning is patterned around the crown, temples or parting line, a hair-loss specialist should assess whether another condition is involved. - Consider evidence-based treatment when appropriate
Topical minoxidil may help support regrowth in some cases, especially when recommended by a clinician. The recent coverage of the Science Progress review also highlighted minoxidil as a possible support option for active shedding.
When should you see a hair specialist?
You should consider a professional hair-loss assessment if:
- shedding is heavy or sudden
- hair loss continues for more than 3–6 months
- the parting line is widening
- the crown or temples are thinning
- there is scalp itching, pain, redness or scaling
- there is a family history of male or female pattern hair loss
- you recently started GLP-1 medication and are losing weight quickly
A proper assessment can help identify whether the problem is temporary telogen effluvium, androgenetic alopecia, a nutritional deficiency, thyroid-related hair loss, or another scalp condition.
GLP-1 medications such as Ozempic, Wegovy, Mounjaro and Zepbound may be associated with temporary hair shedding in some people, especially when weight loss is rapid. The most likely mechanism is telogen effluvium, a stress-related shift in the hair cycle.
For most patients, this type of shedding is not permanent and can improve with stable weight loss, adequate nutrition, correction of deficiencies and appropriate hair-growth support. However, because rapid shedding can also uncover underlying genetic hair loss, early assessment is important.
If you are experiencing hair loss while taking a GLP-1 medication, speak with your prescribing doctor and arrange a professional hair and scalp evaluation.